Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Key words were extracted from the abstracts of the top 100 most cited articles to illustrate a word cloudList of the top 100 most cited articlesNumberYearAuthorTitleJournalCT (ACT)SubcategoryTopic12001Brenner BM, et alEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med4699 (234.95)CSRAAS22001Parving HH, et alThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med2229 (111.45)CSRAAS32008Parving HH, et alAliskiren combined with losartan in type 2 diabetes and nephropathyN Engl J Med769 (59.15)CSRAAS42003Steffes MW, et alSustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) studyJAMA751 (41.72)ESUndefined52006Susztak K, et alGlucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathyDiabetes731 (48.73)MGOS62000Ziyadeh FN, et alLong-term prevention of renal insufficiency excess matrix gene expression and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic miceProc Natl Acad Sci U S A707 (33.67)MGTGF-β72004de Zeeuw D, et alProteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAALKidney Int676 (39.76)CSRAAS82002Schrier RW, et alEffects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokesKidney Int571 (30.05)CSBP92013Fried LF, et al.Combined angiotensin inhibition for the treatment of diabetic nephropathyKidney Int552 (69.00)CSRAAS102004de Zeeuw D, et alAlbuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathyCirculation544 (32.00)CSRAAS112010Tervaert TWC, et alPathologic classification of diabetic nephropathyJ Am Soc Nephrol539 (49.00)PPUndefined122008Zeisberg EM, et alFibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transitionJ Am Soc Nephrol533 (40.92)MGFibroblast132007Kato M, et alMicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressorsProc Natl Acad Sci U S A518 (36.93)MGMiR142003Perkins BA, et alRegression of microalbuminuria in type 1 diabetesN Engl J Med497 (27.61)CST1DM152011Haller H, et alOlmesartan for the delay or prevention of microalbuminuria in type 2 diabetesN Engl J Med494 (49.40)CSRAAS162011de Boer IH, et alTemporal trends in the prevalence of diabetic kidney disease in the United StatesJAMA493 (49.30)ESUndefined172010de Zeeuw D, et alSelective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trialLancet482 (43.82)CSRAAS182013de Zeeuw D, et alBardoxolone methyl in type 2 diabetes and stage 4 chronic kidney diseaseN Engl J Med476 (59.50)CSOS192003Wendt TM, et alRAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathyAm J Pathol438 (24.33)MGAGEs/RAGE202009Kato M, Y, et alTGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTENNat Cell Biol427 (35.58)MGMiR212001Yamamoto Y, et alDevelopment and prevention of advanced diabetic nephropathy in RAGE-overexpressing miceJ Clin Invest390 (19.50)MGAGEs/RAGE222005Gorin Y, et alNox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidneyJ Biol Chem382 (23.88)MGOS232001De Vriese, A, et alAntibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetesJ Am Soc Nephrol361 (18.05)MGVEGF242000Koya D, et alAmelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetesFASEB J356 (16.95)MGOS252004Ichihara A, et alInhibition of diabetic nephropathy by a decoy peptide corresponding to the “handle” region for nonproteolytic activation of proreninJ Clin Invest352 (20.71)MGRAAS262009Groop PH, et alThe presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetesDiabetes348 (29.00)ESUndefined272003Keane WF, et alThe risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL StudyKidney Int345 (19.17)CSRAAS281999Cooper ME, et alIncreased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetesDiabetes345 (15.68)MGVEGF292015Kang HM, et alDefective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis developmentNat Med344 (57.33)MGMetabolism302000Tanji N, et alExpression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal diseaseJ Am Soc Nephrol343 (16.33)MGAGEs/RAGE312004Chow F, et alMacrophages in mouse type 2 diabetic nephropathy: Correlation with diabetic state and progressive renal injuryKidney Int341 (20.06)MGInflammation322017Mann JFE, et alLiraglutide and renal outcomes in type 2 diabetesN Engl J Med337 (84.00)CSGLP-1332011Inoki K, et almTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in miceJ Clin Invest335 (33.50)MGPodocyte342012Wang B, et alSuppression of microRNA-29 expression by TGF-beta 1 promotes collagen expression and renal fibrosisJ Am Soc Nephrol329 (36.44)MGMiR352003Sato A, et alEffectiveness of aldosterone blockade in patients with diabetic nephropathyHypertension326 (18.11)CSRAAS362013Yale JF, et alEfficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney diseaseDiabetes Obes Metab324 (40.38)CSSGLT-2372011Godel M, et alRole of mTOR in podocyte function and diabetic nephropathy in humans and miceJ Clin Invest316 (31.60)MGPodocyte382001Oldfield MD, et alAdvanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE)J Clin Invest316 (15.80)MGAGEs/RAGE392002Onozato ML, et alOxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARBKidney Int314 (16.53)MGRAAS401999Murphy M, et alSuppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cellsJ Biol Chem313 (14.23)MGCTGF412003Berl T, et alCardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathyAnn Intern Med306 (17.00)CSRAAS422000Riser BL, et alRegulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosisJ Am Soc Nephrol305 (14.52)MGCTGF432006Chow FY, et alMonocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated miceKidney Int304 (20.27)MGInflammation442004Bolton WK, et alRandomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathyAm J Nephrol302 (17.76)CSAGEs/RAGE452011Zheng HT, et alTherapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathyDiabetes302 (30.10)MGOS462006Parving HH, et alPrevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspectiveKidney Int299 (19.93)ESUndefined472001Steffes MW, et alGlomerular cell number in normal subjects and in type 1 diabetic patientsKidney Int289 (14.45)PPUndefined482008Wang Q, et alMicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathyFASEB J288 (22.15)MGMiR492006Schmid H, et alModular activation of nuclear factor-kappa B transcriptional programs in human diabetic nephropathyDiabetes279 (18.60)MGTF502010Mann JFE, et alAvosentan for overt diabetic nephropathyJ Am Soc Nephrol277 (25.18)CSRAAS512002Yamagishi S, et alAdvanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cellsJ Biol Chem275 (14.47)MGAGEs/RAGE522003Bakris GL, et alEffects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL studyArch Intern Med274 (15.22)CSRAAS532007Isermann B, et alActivated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosisNat Med266 (19.00)MGInflammation542008Niranjan T, et alThe Notch pathway in podocytes plays a role in the development of glomerular diseaseNat Med264 (20.23)MGPodocyte552007Nakagawa T, et alDiabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathyJ Am Soc Nephrol262 (18.71)MGOS562003Babaei-Jadidi R, et alPrevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamineDiabetes262 (14.56)MGMetabolism572010Krupa A, et alLoss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathyJ Am Soc Nephrol259 (23.55)MGMiR582005Thorn LM, et alMetabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study)Diabetes Care259 (16.19)ESUndefined592003Doublier S, et alNephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin IIDiabetes259 (14.39)MGPodocyte602009Coughlan MT, et alRAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetesJ Am Soc Nephrol258 (21.50)MGAGEs/RAGE612004Mezzano S, et alNF-kappa B activation and overexpression of regulated genes in human diabetic nephropathyNephrol Dial Transplant256 (15.06)MGTF622005Atkins RC, et alProteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathyAm J Kidney Dis252 (15.75)CSRAAS632005Satoh M, et alNAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathyAm J Physiol Renal Physiol251 (15.69)MGOS642005Pohl MA, et alIndependent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: clinical implications and limitationsJ Am Soc Nephrol248 (15.50)CSRAAS652013Sharma K, et alMetabolomics reveals signature of mitochondrial dysfunction in diabetic kidney diseaseJ Am Soc Nephrol247 (30.88)MGMetabolism662007Perkins BA, et alMicroalbuminuria and the risk for early progressive renal function decline in type 1 diabetesJ Am Soc Nephrol247 (17.64)CST1DM672010Sedeek M, et alCritical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathyAm J Physiol Renal Physiol246 (22.36)MGOS682000Wada T, et alUp-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathyKidney Int246 (11.71)MGInflammation692011Woroniecka KI, et alTranscriptome analysis of human diabetic kidney diseaseDiabetes242 (24.20)MGTF702003Kiritoshi S, et alReactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathyDiabetes240 (13.33)MGOS712003Tikellis C, et alCharacterization of renal angiotensin-converting enzyme 2 in diabetic nephropathyHypertension239 (13.28)MGRAAS722012Wang WJ, et alMitochondrial fission triggered by hyperglycemia Is mediated by ROCK1 activation in podocytes and endothelial cellsCell Metab238 (26.44)MGOS732010Jiang T, et alThe protective role of Nrf2 in streptozotocin-induced diabetic nephropathyDiabetes238 (21.55)MGOS742002Flyvbjerg A, et alAmelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibodyDiabetes237 (12.47)MGVEGF752007Eijkelkamp WBA, et alAlbuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) trialJ Am Soc Nephrol236 (16.86)CSRAAS762003Young BA, et alRacial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veteransDiabetes Care236 (13.11)ESUndefined772008Li YJ, et alEpithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuriaAm J Pathol235 (18.08)MGPodocyte782011Wang B, et al.MiR-200a prevents renal fibrogenesis through repression of TGF-beta 2 expressionDiabetes234 (23.40)MGMiR792012Niewczas MA, et alCirculating TNF receptors 1 and 2 predict ESRD in type 2 diabetesJ Am Soc Nephrol233 (25.89)MGInflammation802009Mehdi UF, et alAddition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathyJ Am Soc Nephrol232 (19.33)CSRAAS812008Thallas-Bonke V, et alInhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathwayDiabetes232 (17.85)MGOS822005Jiang T, et alDiet-induced obesity in C57BL/6 J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathwayJ Biol Chem232 (14.50)MGMetabolism832012Putta S, et alInhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathyJ Am Soc Nephrol231 (25.67)MGMiR842008Feldman DL, et alEffects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 ratsHypertension231 (17.77)MGRAAS852006Zhao HJ, et alEndothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic miceJ Am Soc Nephrol231 (15.40)MGOS862005Berl T, et alImpact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trialJ Am Soc Nephrol228 (14.25)CSRAAS872000Nakamura T, et alUrinary excretion of podocytes in patients with diabetic nephropathyNephrol Dial Transplant228 (10.86)MGPodocyte882011Palsamy P, et alResveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signalingBiochim Biophys Acta227 (22.70)MGOS892013Dugan LL, et alAMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial functionJ Clin Invest226 (28.25)MGOS902003Okada S, et alIntercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetesDiabetes226 (12.56)MGInflammation912005Asaba K, et alEffects of NADPH oxidase inhibitor in diabetic nephropathyKidney Int225 (14.06)MGOS922002Forbes JM, et alReduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathyDiabetes223 (11.74)MGRAAS932015Bakris GL, et alEffect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trialJAMA221 (36.83)CSRAAS942002Ha HJ, et alRole of high glucose-induced nuclear factor-kappa B activation in monocyte chemoattractant protein-1 expression by mesangial cellsJ Am Soc Nephrol221 (11.63)MGTF952006Ichihara A, et alProrenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient miceJ Am Soc Nephrol220 (14.67)MGRAAS962014Vallon V, et alSGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita miceAm J Physiol Renal Physiol219 (31.29)MGSGLT-2972008Zhang Z, et alCombination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increaseProc Natl Acad Sci U S A218 (16.77)MGRAAS982016Afkarian M, et alClinical manifestations of kidney disease among US adults with diabetes, 1988 to 2014JAMA217 (43.40)ESUndefined992013Zhong X, et alMiR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetesDiabetologia217 (27.13)MGMiR1002011Kitada M, et alResveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathwayDiabetes217 (27.13)MGOS
Source: Identification of the subcategories of the top 100 articles. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Review / evidence synthesis.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Only full-length original articles were included in this study while other types of articles, such as guidelines, reviews, and meta-analyses, were excluded.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
The evolution and future of diabetic kidney disease research: a bibliometric analysis
Review / evidence synthesis · BMC Nephrology · 2021
Original publication title
The evolution and future of diabetic kidney disease research: a bibliometric analysis
© The Author(s) 2021
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Diabetic kidney disease (DKD) is one of the most important complications of diabetic mellitus. It is essential for nephrologists to understand the evolution and development trends of DKD.
Source: BackgroundAbstract: What methods does the paper describe?
Based on the total cited numbers in the Web of Science Core Collection, which was searched through September 28th, 2020, we performed a bibliometric analysis of the top 100 most cited full-length original articles on the subject of DKD. The timespans, authors, contributions, subcategories, and topics of those 100 articles were analysed. In addition, the evolution of topics in DKD research was investigated.
Source: MethodsAbstract: Results
There were 23,968 items under the subject of DKD in the Web of Science Core Collection. The top 100 cited articles, published from 1999 to 2017, were cited 38,855 times in total. Researchers from the USA contributed the most publications. The number of articles included in ‘Experimental studies (EG)’, ‘Clinical studies (CS)’, ‘Epidemiological studies (ES)’, and ‘Pathological and pathophysiological studies (PP)’ were 65, 26, 7, and 2, respectively. Among the 15 topics, the most popular topic is the renin-angiotensin-aldosterone system (RAAS), occurring in 26 articles, including 6 of the top 10 most cited articles.
The evolution of topics reveals that the role of RAAS inhibitor is a continuous hotspot, and sodium-glucose cotransporter 2 (SGLT-2) inhibitor and glucagon-like peptide 1 (GLP-1) agonist are two renoprotective agents which represent novel therapeutic methods in DKD. In addition, the 26 clinical studies among the top 100 most cited articles were highlighted, as they help guide clinical practice to better serve patients.
Source: ResultsAbstract: Conclusions
This bibliometric analysis of the top 100 most cited articles revealed important studies, popular topics, and trends in DKD research to assist researchers in further understanding the subject.
Source: ConclusionsAuthors’ abstract
Background
Diabetic kidney disease (DKD) is one of the most important complications of diabetic mellitus. It is essential for nephrologists to understand the evolution and development trends of DKD.
Methods
Based on the total cited numbers in the Web of Science Core Collection, which was searched through September 28th, 2020, we performed a bibliometric analysis of the top 100 most cited full-length original articles on the subject of DKD. The timespans, authors, contributions, subcategories, and topics of those 100 articles were analysed. In addition, the evolution of topics in DKD research was investigated.
Results
There were 23,968 items under the subject of DKD in the Web of Science Core Collection. The top 100 cited articles, published from 1999 to 2017, were cited 38,855 times in total. Researchers from the USA contributed the most publications. The number of articles included in ‘Experimental studies (EG)’, ‘Clinical studies (CS)’, ‘Epidemiological studies (ES)’, and ‘Pathological and pathophysiological studies (PP)’ were 65, 26, 7, and 2, respectively. Among the 15 topics, the most popular topic is the renin-angiotensin-aldosterone system (RAAS), occurring in 26 articles, including 6 of the top 10 most cited articles.
The evolution of topics reveals that the role of RAAS inhibitor is a continuous hotspot, and sodium-glucose cotransporter 2 (SGLT-2) inhibitor and glucagon-like peptide 1 (GLP-1) agonist are two renoprotective agents which represent novel therapeutic methods in DKD. In addition, the 26 clinical studies among the top 100 most cited articles were highlighted, as they help guide clinical practice to better serve patients.
Conclusions
This bibliometric analysis of the top 100 most cited articles revealed important studies, popular topics, and trends in DKD research to assist researchers in further understanding the subject.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12882-021-02369-z.
Publication and source details
Original title: The evolution and future of diabetic kidney disease research: a bibliometric analysis
Yi Wei; Zongpei Jiang
BMC Nephrology · 2021
© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T12:54:37.584045+00:00
DOI: 10.1186/s12882-021-02369-z · PMC8084262